The Latest Breaking News from Novartis

Monte Rosa Therapeutics shares nearly doubled Monday on a deal with Novartis to develop treatments for immune system conditions.

Patient groups should be playing a central role in Canada’s health-care system, advocating for their members by promoting the visibility of their conditions, pushing for more rapid and accurate diagnoses and lobbying for the introduction and funding of new treatments and drugs that may help relieve their members’ symptoms and…

Novartis shows improving price performance, earning an upgrade to its IBD Relative Strength Rating

A renaissance is stirring in cholesterol treatment, and it could drive Merck, Novartis and other stocks higher, while delivering new choices for millions of patients.

A Relative Strength Rating upgrade for Novartis ADR shows improving technical performance. Will it continue?

Novartis paved the way for radiopharmaceuticals. Now, Big Pharma thinks it can do better — and biotech stocks have soared on a spate of deals.

Novartis stock jumped Tuesday after the drugmaker topped first-quarter sales and earnings forecasts, and raised its full-year outlook.

Biotech stocks heated up Thursday as Novartis scooped up a licensing pact with Arvinas and Janux was said to be exploring strategic options.

Next-generation cancer therapies are here. AstraZeneca - already an oncology leader - is going down the path of radiopharmaceuticals with its purchase of Fusion. Along with the other potential blockbuster drugs in its pipeline, this should bode well for growth at AZN.